COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00332969
Recruitment Status : Completed
First Posted : June 2, 2006
Last Update Posted : March 31, 2017
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
This study will investigate the efficacy of treatment with octroetide in patients with primary inoperable thymoma to reduce tumor size.

Condition or disease Intervention/treatment Phase
Thymoma Drug: Octreotide Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy of Medical Treatment With Octreotide in Patients With Primary Inoperable Thymoma to Reduce Tumor Size
Study Start Date : September 2005
Actual Primary Completion Date : October 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Thymus Cancer

Arm Intervention/treatment
Experimental: Sandostatin Drug: Octreotide

Primary Outcome Measures :
  1. Shrinkage of tumor size and diameter of 3 respectively 6 months [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Resection status after 3 respectively 6 months [ Time Frame: 3 - 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female patients aged >18 years
  2. Inoperability of thymic tumor. Inoperability is defined as at least adherence of the tumor to the neighbour organs, suspicious to infiltrate neighbour organs so that R0 resection cannot be expected.
  3. Positive result in SMS-szintigraphy,
  4. Thymomas of all WHO based histological subtypes (Rosai, 1999; Travis 2004) at Masaoka stage III based on histological examination of core biopsies or resection specimens.
  5. Patients with and without thymoma associated paraneoplastic syndrome
  6. Demonstrated tolerance to a test dose of s.c. octreotide injection at Visit 1.

Exclusion Criteria:

  1. Performance status 0,1, or 2 (ECOG)
  2. Symptomatic cholelithiasis,
  3. Pretreatment with octreotide (longn acting release) within the 3 months
  4. Patient has received any other investigational agents within 28 days of first day of study drug dosing
  5. Patient is < 5 years free of another primary malignancy except: if the other primary malignancy is not currently clinically significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Existence of any other malignant disease is not allowed
  6. Grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study)

Other protocol-defined inclusion/exclusion criteria apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00332969

Layout table for location information
Novartis Investigative Site
Regensburg, Germany
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmeceuticals
Publications of Results:
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals Identifier: NCT00332969    
Other Study ID Numbers: CSMS995ADE13
First Posted: June 2, 2006    Key Record Dates
Last Update Posted: March 31, 2017
Last Verified: November 2011
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Open label
phase II
clinical trial
Additional relevant MeSH terms:
Layout table for MeSH terms
Thymus Neoplasms
Neoplasms, Complex and Mixed
Neoplasms by Histologic Type
Thoracic Neoplasms
Neoplasms by Site
Lymphatic Diseases
Gastrointestinal Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents